Please ensure Javascript is enabled for purposes of website accessibility

Grail, Backed by Jeff Bezos and Bill Gates, Files for IPO

By Taylor Carmichael – Sep 9, 2020 at 3:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company seeks to detect cancer from a simple blood test.

Cancer diagnostic specialist Grail today filed for an initial public offering (IPO) on the Nasdaq, with the stock to trade under the ticker symbol GRAL. The start-up has raised almost $2 billion in seed money in four rounds of private investing since 2016. In its 2019 round of funding, Grail's valuation was estimated at $3.2 billion. Some of the company's notable backers include Jeff Bezos, the richest man in the world, and Bill Gates, the second richest.

Grail was spun out of gene-sequencing giant Illumina (ILMN -1.65%) four years ago. In its S-1 filing, the company wrote, "Using our platform technology, we have developed a multi-cancer early detection blood test that has demonstrated in clinical studies the ability to detect more than 50 types of cancer, across all stages, and localize the cancer signal with a high degree of accuracy, from a single blood draw." 

The letters IPO sitting on stacks of coins.

Image source: Getty Images.

Grail is doing some massive clinical trials to prove its test is effective at detecting cancer, enrolling 165,000 volunteers in three large-scale studies. The company hopes to launch a multi-cancer early detection test, Galleri, in 2021. 

Grail is competing with a $10 billion company, Guardant Health (GH -1.71%), and private company Thrive, a start-up that came out of Johns Hopkins. While Guardant Health has an approved liquid biopsy that will profile the genes of cancer patients, no company has approval yet from the Food and Drug Administration to sell a blood test to determine if people have cancer.

Taylor Carmichael has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Guardant Health and Illumina. The Motley Fool recommends Nasdaq. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Guardant Health Stock Quote
Guardant Health
GH
$50.64 (-1.71%) $0.88
Illumina Stock Quote
Illumina
ILMN
$215.38 (-1.65%) $-3.61
Nasdaq Stock Quote
Nasdaq
NDAQ
$66.38 (-1.15%) $0.77

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.